Twelve week post-treatment follow-up predicts sustained virological response to pegylated interferon and ribavirin therapy in HIV/hepatitis C virus co-infected patients

Journal of Antimicrobial Chemotherapy

Volumn 66, Issue 6, 2011, Pages 1351-1353

  Rivero Juárez, Antonio ^a   Mira, José A ^b   Pérez Camacho, Inés ^c   Macías, Juan ^b   Camacho, Angela ^a   Neukam, Karin ^b   Torre Cisneros, Julián ^a   Merchante, Nicolás ^b   Pineda, Juan A ^b   Rivero, Antonio ^a  

^a HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^b HOSPITAL UNIVERSITARIO DE VALME   (Spain)

^c HOSPITAL DE PONIENTE   (Spain)

Author keywords

Hepatitis C virus; Human immunodeficiency virus; Relapse; Sustained viral response

Indexed keywords

PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS RNA;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG WITHDRAWAL; EVALUATION; FEMALE; FOLLOW UP; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIMIT OF DETECTION; LIVER CIRRHOSIS; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; PATIENT COMPLIANCE; POLYMERASE CHAIN REACTION; PREDICTION; PREDICTIVE VALIDITY; PROBABILITY; PROSPECTIVE STUDY; QUANTITATIVE ANALYSIS; RELAPSE; SEROLOGY; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; UNSPECIFIED SIDE EFFECT;

ADULT; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HEPATITIS C; HIV INFECTIONS; HUMANS; INTERFERON ALFA-2A; INTERFERON ALFA-2B; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RIBAVIRIN; RNA, VIRAL; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 79956028897     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkr091     Document Type: Article

References (10)

1. Maylin S, Martinot-Peignoux M, Moucari M et al. Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis C. Gastroenterology 2008; 135: 821-9.
2. George SL, Bacon BR, Brunt EM et al. Clinical, virologic, histologic and biochemical outcomes after successful HCV therapy: a 5-year follow-up of 150 patients. Hepatology 2009; 49: 729-38.
3. Veldt B, Saracco G, Boyer N et al. Long term clinical outcome of chronic hepatitis C patients with sustained virological response to interferon monotherapy. Gut 2004; 53: 1504-8.
4. Ghany MG, Strader DB, Thomas DL et al. Diagnosis, management and treatment of hepatitis C: an update. AASLD Practice Guidelines. Hepatology 2009; 49: 1335-74.
5. Zeuzem S, Heathcote EJ, Shiffman ML et al. Twelve weeks of follow-up is sufficient for the determination of sustained virologic response in patients treated with interferon alpha for chronic hepatitis C. J Hepatol 2003; 39: 106-11.
6. Martinot-Peignoux M, Stern C, Maylin S et al. Twelve weeks posttreatment follow-up is as relevant as 24 weeks to determine the sustained virologic response in patients with hepatitis C virus receiving pegylated interferon and ribavirin. Hepatology 2010; 51: 1122-6.
7. Medrano J, Barreiro P, Resino S et al. Rate and timing of hepatitis C virus relapse after a successful course of pegylated interferon plus ribavirin in HIV-infected and HIV-uninfected patients. Clin Infect Dis 2009; 49: 1397-401.
8. Soriano V, Puoti M, Sulkowski M et al. Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel. AIDS 2007; 21: 1073-89.
9. Aghemo A, Rumi MG, De Nicolla S et al. Twelve-week posttreatment follow-up predicts a sustained virological response to pegylated interferon and ribavirin therapy. Hepatology 2010; 52: 1170-1.
10. Gerotto M, Dal Pero F, Bortoletto G et al. Hepatitis C minimal residual viremia (MRV) detected by TMA at the end of Peg-IFN plus ribavirin therapy predicts post-treatment relapse. J Hepatol 2006; 44:83-7.